Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eHealth

- PMLiVE

Applying real-world evidence to orphan drugs

How to prove pharma’s innovative treatments really can bring about positive outcomes

- PMLiVE

Amgen and UCB’s romosozumab hits goals in male osteoporosis

Firms will discuss data with regulators before planning a new male licence application

- PMLiVE

Positive trials bring Pfizer closer to new use for Xeljanz

Rheumatoid arthritis drug performs in two ulcerative colitis trials

- PMLiVE

GW ascendant as epilepsy drug clears phase III trial

Epidiolex proves effective in controlling seizures in children with Dravet syndrome

- PMLiVE

EMA starts review of Gilead’s Zydelig on ‘serious’ safety concerns

Trials of the leukaemia treatment have been halted while the investigation is underway

- PMLiVE

A better direction

Could behavioural science be the key to improving patient outcomes?

The new EU clinical trial lay summaries

New regulations will require both a trial summary and a lay person’s summary

- PMLiVE

The new EU clinical trial lay summaries

New regulations will require both a trial summary and a lay person’s summary

- PMLiVE

Genital herpes vaccine candidate promising in phase II

Genocea Biosciences’ GEN-003 found to reduce recurrence and transmission of the virus

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

Amazing Africa

What the continent can teach us about digital health innovation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links